Barings LLC Maintains Position in C.R. Bard, Inc. (BCR)

Barings LLC continued to hold its position in C.R. Bard, Inc. (NYSE:BCR) during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,716 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Barings LLC’s holdings in C.R. Bard were worth $924,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Halcyon Management Partners LP bought a new stake in C.R. Bard during the 2nd quarter worth approximately $25,746,000. GLG Partners LP bought a new stake in C.R. Bard during the 2nd quarter worth approximately $17,861,000. Glovista Investments LLC bought a new stake in C.R. Bard during the 2nd quarter worth approximately $221,000. Tudor Investment Corp ET AL raised its stake in C.R. Bard by 8,096.0% during the 2nd quarter. Tudor Investment Corp ET AL now owns 151,871 shares of the medical instruments supplier’s stock worth $48,008,000 after acquiring an additional 150,018 shares during the period. Finally, HighTower Advisors LLC raised its stake in C.R. Bard by 15.3% during the 2nd quarter. HighTower Advisors LLC now owns 2,698 shares of the medical instruments supplier’s stock worth $854,000 after acquiring an additional 358 shares during the period. Institutional investors own 79.22% of the company’s stock.

C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter last year, the firm posted $2.54 EPS. The business’s revenue was up 5.2% on a year-over-year basis.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.32%. C.R. Bard’s dividend payout ratio (DPR) is 13.67%.

A number of equities research analysts have commented on the stock. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the company’s stock. C.R. Bard has an average rating of “Hold” and an average price target of $292.00.

In related news, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $322.00, for a total value of $2,700,936.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The disclosure for this sale can be found here. Insiders have sold a total of 62,327 shares of company stock worth $19,931,334 in the last quarter. Insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Barings LLC Maintains Position in C.R. Bard, Inc. (BCR)” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2017/10/13/barings-llc-maintains-position-in-c-r-bard-inc-bcr.html.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply